GLP1R and type 2 diabetes mellitus: Lira is an approved antidiabetic drug that acts as an incretin mimetic GLP-1R agonist and is increasingly used to improve glycemic control, reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes mellitus (T2DM) (Marso et al., 2016).